Activated CDC42 kinase 1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Activated CDC42 kinase 1 as ChEMBL target CHEMBL4599, mapped to UniProt Q07912. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Activated CDC42 kinase 1 matters
Activated CDC42 kinase 1 is reviewed as Activated CDC42 kinase 1 (UniProt Q07912); the current evidence base includes 30 approved drugs, 2139 compounds, and 344 assays, with lead potency reaching pChEMBL 9.7.
Activated CDC42 kinase 1 Sequence length is 1038 aa.
Review this target as Activated CDC42 kinase 1, mapped to UniProt Q07912. Sequence length is 1038 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 30 approved drugs, 2139 compounds, and 344 assays for this target. The dominant activity type is IC50. CHEMBL2087874 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL2087874 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Activated CDC42 kinase 1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q07912, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2087874
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL5400397
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL2087873
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL2087875
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL5408748
|
9.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
LORLATINIB
CHEMBL3286830
|
2018 |
|
|
LAROTRECTINIB
CHEMBL3889654
|
2018 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
VEMURAFENIB
CHEMBL1229517
|
2011 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |